Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
Cardiotoxicity is a potentially life-threatening consequence of treatment with doxorubicin. Without reliable predictive or monitoring tests for early intervention, preventive methods are warranted. This study tested the hypothesis that a 1-hour infusion of doxorubicin would reduce the incidence of cardiotoxicity compared with historical incidences. Inclusion criteria for this retrospective trial were a minimum of three doses of doxorubicin administered as a 1-hour infusion in patients with at least two echocardiographic or electrocardiographic examinations during the course of treatment (median cumulative dose, 120 mg/m2). Of 133 dogs, 16 (12%) developed electrocardiographic abnormalities during or after treatment, which was statistically lower than the historical incidence of 17.7% (31 of 175 dogs). Only seven dogs (5.3%) developed abnormalities during the course of therapy. Three (2%) developed congestive heart failure.
Gillings
Sarah
S
Animal Cancer Specialists, Seattle, WA 98125, USA.
Johnson
Jeffrey
J
Fulmer
Amanda
A
Hauck
Marlene
M
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects*; D004283:Dog Diseases / Q000139:chemically induced*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004452:Echocardiography / Q000662:veterinary; D004562:Electrocardiography / Q000662:veterinary; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced / Q000662:veterinary*; D007275:Injections, Intravenous; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary; D012189:Retrospective Studies; D012307:Risk Factors
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin